Back to trial detailsIntake questionnaire
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Applying to Houston Methodist Hospital · Houston, Texas
Answer a few short questions to share with the research team.
0 of 3 answered